Published 14 days ago • loading... • Updated 14 days ago

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

Summary by centerforbiosimilars.com

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All

Left

Center

Right

centerforbiosimilars.com

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

14 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated14 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

centerforbiosimilars.com broke the news in 14 days ago on Saturday, February 8, 2025.

Sources are mostly out of (0)

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

1 Articles

1 Articles

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics